Initial dysphoric response to first administration of neuroleptics;Die initial dysphorische reaktion (IDR) auf die ersteinnahme von neuroleptika

Nervenarzt

Volumn 75, Issue 1, 2004, Pages 36-43

  Schimmelmann, B Graf ^a   Schacht, M ^a   Perro, C ^a   Lambert, M ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antipsychotics; Initial dysphoric reaction; Schizophrenia; Subjective well being

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; HALOPERIDOL; MESORIDAZINE; NEUROLEPTIC AGENT; PERAZINE; PLACEBO; THIORIDAZINE; TIOTIXENE;

AFFECT; AGE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DYSPHORIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GENDER; HOSTILITY; HUMAN; INITIAL DYSPHORIC RESPONSE; MEDICAL LITERATURE; MENTAL DISEASE; PATHOGENESIS; PHENOMENOLOGY; RATING SCALE; SCHIZOPHRENIA; TREATMENT OUTCOME; WELLBEING;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BRIEF PSYCHIATRIC RATING SCALE; DEPRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PERSONALITY INVENTORY; PROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SICK ROLE;

EID: 1342344811     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-003-1544-z     Document Type: Article

References (51)

1. Abi-Dargham A, Rodenhiser J, Printz D et al. (2000) Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA 97: 8104-8109
2. Anderson BG, Reker D, Volavka J (1981) Prolonged adverse effects from haloperidol in normals. N Engl J Med 30S: 643-644
3. Awad AG (1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull 19: 609-618
4. Ayers T, Liberman RP, Wallace CJ (1984) Subjective response to antipsychotic drugs: Failure to replicate predictions of outcome. J Clin Psychopharamcol 4: 89-93
5. Bartkó G, Herczeg I, Békésy M (1987) Predicting outcome of neuroleptic treatment in the basis of subjective response and early clinical improvement. J Clin Psychiatry 48: 363-365
6. Belmaker R, Wald D (1977) Haloperidol in normals. Br J Psychiatry 131: 222-223
7. Berger BD (1972) Conditioning of food aversions by injections of psychoactive drugs. J Comparative Physiology and Psychology 81: 21-26
8. Bruun RD (1988) Subtle and unrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 145: 621-624
9. Caine ED, Polinsky RJ (1979) Haloperidol induced dysphoria in patients with Tourette's syndrome. Am J Psychiatry 136: 1216-1217
10. Carpenter WT, Heinrichs DW, Wagman A (1988) Deficit and nondeficit forms of schizophrenia: The concept. Am J Psychiatry 145: 578-583
11. Fink EB, Braden W, Qualls CB (1982) Predicting pharamcotherapy outcome by subjective response. J Clin Psychiatry 43: 272-275
12. Gaebel W, Pietzcker A, Ulrich G, Schley J, Müller-Oerling-hausen B (1988) Predictors of neuroleptic treatment response in acute schizophrenia: Results of a treatment study with perazine. Pharmacopsychiatry 21: 384-386
13. Giardini V (1985) Influence of housing conditions and state of partner on conditioning and extinction of taste aversions to lithium and chlorpromazine. Psychopharmacology 86: 96-101
14. Heinrich K, Tegeler J (1983) Dyskognitive, apathische und extrapyramidale Syndrome bei Langzeit-Neurolepsie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Erlangen
15. Helmchen H und Hippius H (1967) Depressive Syndrome im Verlauf neuroleptischer Therapie. Nervenarzt 38: 455-458
16. Helmchen H (1983) Prediction of course and therapeutic response in psychiatric disease. Pharmacopsychiatry 16: 173-174
17. Henninger G, DiMascio A, Klerman GL (1965) Personality factors invariability of response to phenothiazines. Am J Psychiatry 121: 1091-1094
18. Hogan TP, Awad AG, Eastwood R (1983) A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 13: 177-183
19. Hogan TP, Awad AG, Eastwood MR (1985) Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 30: 246-248
20. Hogan TP, Awad AG (1992) Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 22: 347-352
21. Jellinek T, Gardos G, Cole JO (1981) Adverse effects of antiparkinson drug withdrawal. Am J Psychiatry 138: 1567-1571
22. Kapfnammer HP, Rüther E (1988) Depot-Neuroleptika. Springer, Berlin Heidelberg New York Tokio
23. Kay S, Fiszbein A, Opler L (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276
24. Kendler KS (1976) A medical student's experience with akathisia (letter to ed). Am J Psychiatry 133: 454-455
25. Lambert M, Graf Schimmelmann B, Haasen C, Naber D (2002) Subjektive Befindlichkeit unter neuroleptischer Therapie: Relevant für die Psychopharmakotherapie psychotischer Patienten? Psychopharmakotherapie 2: 53-S9
26. Lewander T (1994) Neuroleptics and the neuroleptic-induced deficit syndrom. Acta Psychiatr Scand 89(suppl 380): 8-13
27. Linden M, Nather J, Wilms HU (1988) Zur Definition, Bedeutung und Messung der Krankheitskonzepte von Patienten. Die Krankheitskonzeptskala (KK-Skala) für schizophrene Patienten. Fortschr Neurol Psychiatr 56: 35-43
28. Lindström LH (1994) Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side-effects of antipsychotic drugs. Acta Psychiatr Scand Suppl 380: 74-76
29. May PRA, Van Putten T, Yale C et al. (1976) Predicting individual responses to drug treatment in schizophrenia: A test dose model. J Nerv Ment Dis 162: 177-183
30. Naber D (1995) A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 10 (suppl 3): 133-138
31. Naber D, Moritz S, Lambert M et al. (2001) Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophr Res 30;50(1-2): 79-88
32. Overall JE, gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812
33. Pi E, Sramek J,Johnson T, Herrera J et al. (1990) Subjective neuroleptic response and treatment outcome under open and double-blind conditions - a preliminary report. Prog Neuro-Psychopharamcol Biol Psychiatr 14: 921-928
34. Priebe S (1992) Die Bedeutung der Patientenmeinung. Initiale Bewertung und Verlauf psychiatrischer Therapie. Hogrefe, Göttingen
35. Russell KH, Hagenmeyer-Houser SH, Sanberg PR (1987) Haloperidol-induced defecation asa possible model for neuroleptic anxiety syndrome. Psychopharmacology 91: 45-49
36. Russell KH, Hagenmeyer-Houser SH, Sanberg PR (1987) Haloperidol produced increased defecation in rat's habituated environment. Bulletin of the Psychonomic Society 25: 13-16
37. Sanberg PR, Russell KH, Hagenmeyer-Houser SH etal. (1989) Neuroleptic-induced emotional defecation: Effects of scopolamine and haloperidol. Psychopharmacology 99: 60-63
38. Singh MM, Smith JM (1973) Kinetics and dynamics of response to haloperidol in acute schizophrenia: A longitudinal study of the therapeutic process. Compr Psychiatry 14: 393-414
39. Singh MM (1976) Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 37: 191-196
40. Singh MM, Kay SR (1979) Dysphoric response to neuroleptic treatment in schizophrenia: Its relationship to autonomic arousal and prognosis. Biol Psychiatry 14: 277-294
41. Spanagel R, Weiss F (1999)The dopamine hypothesis of reward: past and current status. Trends Neurosci 22: 521-525
42. Van Putten T, May PRA (1978). Akinetic Depression" in schizophrenia. Arch Gen Psychiatry 35: 1101-1107
43. Van Putten T, May PRA (1978) Subjective response as a predictor of outcome in pharmacotherapy. The consumer has a point. Arch Gen Psychiatry 35: 477-480
44. Van Putten T, May PRA, Jenden DJ, Cho AK, Yale C (1980) Plasma and saliva levels of chlorpromazine and subjective response. Am J Psychiatry 137: 1241-1242
45. Van Putten T, May PRA, Marder SR, Wittmann L (1981) Subjective response to antipsychotic drugs. Arch Gen Psychiatry 38: 187-190
46. Van Putten T, May PRA, Marder SR (1984) Response to antipsychotic medication: The doctor's and the consumer's view. Am J Psychiatry 141: 16-19
47. Van Pulen T, Marder SR (1987) Behavioural toxicity of antipsychotic drugs. J Clin Psychiatry 48: 13-19
48. Van Putten T, Marder SR, Mintz J (1990) A controlled dose comparison of Haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 47: 754-758
49. Voruganti L, Slomka P, Zabel P et al. (2001) Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D2 binding ratios on SPECT imaging. Neuropsychopharmacology 25: 642-650
50. White K, Busk J, Eaton E, Gomez G, Razani J, Sloane RB (1981) Dysphoric response to neu roleptics as a predictor of treatment outcome with schizophrenics. A comparative study of Haloperidol vs. Mesoridazine. Int Pharmacopsychiat 16: 34-38
51. Wise RA (1996) Neurobiology of addiction. Curr Opin Neurobiol 6(2): 243-251